{Reference Type}: Journal Article
{Title}: Leading medulloblastoma to a differentiation end.
{Author}: Nör C;Ramaswamy V;
{Journal}: Cancer Cell
{Volume}: 42
{Issue}: 8
{Year}: 2024 Aug 12
{Factor}: 38.585
{DOI}: 10.1016/j.ccell.2024.07.011
{Abstract}: Effective and less toxic therapies for medulloblastoma have proved to be highly elusive. In this issue of Cancer Cell, Yang et al. show that thyroid hormone treatment leads to the activation of neurogenic differentiation factor 1 (NeuroD1) and differentiation of medulloblastoma cells through reversing EZH2-mediated transcriptional repression of NeuroD1.